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American Foulbrood (AFB) of honey bees is the most contagious and destructive infectious 
disease affecting the larval and pupal stages of honey bees (Apis mellifera) and other Apis 
species. The causative agent, Paenibacillus larvae, is a Gram-positive bacterium that can 
produce over one billion spores in each infected larva. AFB occurs throughout the world 
and leads to considerable losses in apiculture and pollination. The disease is classified 
within the World Organization for Animal Health (OIE) list and considered to be of socio-
economic impact and significance in the international trade of bees and bee products.  
Only bacterial spores are capable of inducing the infection. Spores can remain viable in 
comb and woodenware for decades and survive adverse conditions (desiccation, high 
temperatures, ultraviolet light exposure) and contact with standard disinfectants. The 
spread of the disease is facilitated by regular beekeeping practices, including exchanging 
hive components between colonies, maintaining many hives in a confined area, and 
trading queens, package bees and honey. 
Clinical signs 
Clinical signs are diverse and depend on the genotype involved. In severely infected 
colonies, the combs have a mottled appearance caused by a pattern of healthy capped 
brood, uncapped cells containing the remains of diseased larvae, and empty cells. The 
capping of a cell that contains a diseased larva appears moist and darkened and becomes 
concave and punctured as the infection progresses. Also, the larva or pupa changes their 




consistency and can be drawn out as threads when a probe is inserted into the larval 
remains and removed from the cell (match-stick test). Finally, one month or more after 
the larva becomes ropy, the remains of the diseased brood dry out to form typical hard, 
dark scales that are brittle and adhere firmly to the lower sides of the cell. If death occurs 
in the pupal stage, the pupal tongue protrudes from the pupal head, extending to the top 
of the brood cell or may angle back towards the bottom of the cell. The protruding tongue 
is one of the most characteristic signs of the disease, although it is rarely seen. The tongue 
may also persist on the dried scale.  
 
Genotypes: 
 Diverse genotypes of the pathogen with different virulence have been identified using 
rep-PCR fingerprinting and exposure bioassays to infect young larvae, ERIC-PCR 
amplification has shown four P. larvae genotypes, named ERIC I, II, III, and IV. This typing 
scheme correlates with phenotypic differences, including spore surface configuration, 
colony morphology, and virulence. Different genotypes differ in virulence; comparative 
exposure bioassays demonstrated that ERIC II is more virulent on the larval level than ERIC 
I.  Genotypes ERIC I and II are regularly isolated from infected colonies worldwide, 
whereas ERIC III and IV are only represented by few isolates in Type Culture Collections. 
Only ERIC I and II are of practical importance.  
 
Control 
Different methods of treating AFB-colonies are used, including the destruction of infected 
hives by burning and antibiotic treatments. Nevertheless, antibiotics are not currently 
recommended due to increasing resistance among bacterial populations and the presence 
of residual antibiotics on honey bee products. Resistance to tetracycline is mainly due to 
the acquisition of the Tet L determinant associated with mobile elements. The extensive 
use of tetracycline and oxytetracycline to control AFB in some North and South American 
countries has contributed to an increase of TcR in P. larvae, by enhancing the interspecific 




transfer of tet(L) genes from other gram-positive bacteria, such as the ubiquitous species 
of Bacillus. European Community legislation limits the presence of antibiotics in honey, 
excluding their use for AFB therapy.  Moreover, the accumulation of antibiotic resistance 
in the gut microbiota of bees has been detected and might additionally lead to bee colony 
collapse. Due to the non-specificity of antibiotics, both harmful and good gut microbes are 
killed when ATB were applied to the hives. This toxicity decreases the gut diversity of the 
honey bee which in turn makes them less healthy.  
With the increasing demand for organic honey and the reduction of dependence on 
antibiotics, it is evident that an Integrated Pest Management (IPM) approach is needed to 
ensure the sustainability of the beekeeping industry. Within this context, the use of phage 
therapy seems promising and able to combine with an IPM strategy.  
 
Bacteriophages and phage therapy 
As an ancient proverb states, “The enemy of my enemy is my friend.” The so-called strictly 
lytic or virulent bacteriophages (phages) can certainly be considered enemies of “bad” 
bacteria and thereby our friends. The phage potential as antibacterial agents was 
recognized almost immediately upon the first generally accepted descriptions of these 
viruses as transmissible bacteriolytic entities 
Bacteriophages are viruses that only infect and replicate in bacteria and are highly specific 
for their hosts. Phages take advantage of bacteria biosyntethic machinery by directing it 
toward the synthesis of more phages able to induce the bacterial lysis and phage release 
to the environmet. New infection cycles will be triggered as soon as phages reach 
available hosts nearby. 
A single type of bacteria can have many phages that are specific for that bacterium. The 
extreme specificity of phages is observed as their ability to bind and infect only their 
target bacterium and leave other cell types, bacterial and eukaryotic, unharmed, showing 
no toxicity to plants, animals or humans. The specific killing activity of phages makes them 




Phage therapy is the therapeutic use of bacteriophages to kill bacterial cells by infecting 
and lysing bacteria. Since bacteriophages have shown high efficacy in treating bacterial 
infections in humans and animals, phage therapy seems to be an attractive alternative to 
control AFB.  
The course of a replication cycle is the criterion to divide bacteriophages into lytic and 
lysogenic ones. The release of lytic phage progeny from infected cells requires bacterial 
lysis. Scientific studies on phage lytic mechanisms contribute to the development of phage 
therapy. Some lytic bacteriophages use single proteins, amurins, to inhibit the synthesis of 
peptidoglycan - However, most of them utilize two groups of proteins to kill the host cell. 
The first ones, holins, synergize with the second ones, endolysins, to cause lysis. Together, 
they make up the holin–lysin systems.  
Phages that infect P. larvae were isolated as early as the 1950s from a variety of sources, 
including AFB-infected larvae, soil samples, commercial beeswax products, and from 
lysogenic P. larvae strains.  Only in recent years, P. larvae genomes have been sequenced 
and analyzed (n=48 and increasingly). 
 
Pros and cons:  
Nevertheless, phage therapy has advantages and disadvantages:  
Within the advantages, phages are: 
 1) bactericidal agents (bacteria that have been successfully infected by obligately lytic 
phages are unable to regain their viability), 2) auto "dosing" (phages can increase in 
number over the course of treatment); 3)  high specificity  (tend only minimally to disrupt 
normal microbiota due to its high specificity); 4) narrower potential for inducing resistance 
(the relative narrow host range exhibited my most phages limits the number of bacterial 
types with which selection for specific phage-resistance mechanisms can occur); 5) lack of 
cross-resistance with antibiotics (phages are equally effective against antibiotic-sensitive 
and antibiotic-resistant bacteria ), 6) show negligible inherent toxicity (consists mostly of 
nucleic acids and proteins), 7) can be regarded as natural products (they are natural 




versatile in application forms, different phages can be mixed in a cocktail to have a greater 
spectrum of activity); 9) Biofilm clearance (biofilms tend to be  more resistant to 
antibiotics, phages, however, have demonstrated to clear biofilms due to their potential 
to penetrate into biofilms; 10) relatively low cost (the production of phages involves a 
combination of host growth and subsequent phage purification which is less expensive 
than costs for pharmaceutical production) 
Within the disadvantages: 
1) The problem of narrow host range (due to its high specificity some bacterial strains of 
the target pathogen are not killed by a specific phage; it could be avoided by using phage 
cocktails); 2) the unfamiliarity  with phages (phages as viruses could be misinterpreted by 
the general public as being equivalent to viral pathogens that cause human diseases);  3) 
phages should be fully sequenced and characterized  (to avoid toxin-carrying phages and 
genes with significant homology to antibiotic resistance genes)  
 
Starting point to Endpoint goal   
 
1) Phage isolation for phage therapy  
Enrichment of samples from environmental sources: larvae, debris from hives, soil under 
apiaries, wax, etc. , centrifugation, and ultracentrifugation steps. 
 
2) Preliminary host-range determination 
Prior to animal testing there are various approaches toward characterizing phages for 
antibacterial effectiveness. Most important is the range of bacteria targeted. As a minimal 
requirement for phage therapy, a phage should be able to infect the bacterial isolates it is 
supposed to be targeting and to display reasonable specificity so that non-target bacteria 
are not affected. 
 
3) Further host-range determination 
Functional assays, such as lytic tests spanning a variety of bacterial strains, are a valuable 
method to identify appropriate phages for field testing.  
 




In addition to the assessment of host range (previous section), other phage characteristics 
such as burst size, ability to display lysogeny, and general plaque morphology should be 
evaluated. 
 
5) Genomics and bioinformatic characterization 
Genome sequencing followed by in silico analyses, especially to exclude phages carrying 
bacterial virulence factor genes. Also, it is advantageous to exclude phages carrying 
lysogeny-associated genes.  
 
6) In vivo phage  characterization 
Potential cytotoxic effects can also be evaluated using eukaryotic cell lines 
 
7) In situ characterization 
In situ phage assessment within other organisms or surrogates, such as during animal 
testing.  Such assessment includes in terms of safety to the host during treatment, though 
in practice few side effects with phage therapy have been detected 
 
8) Enzybiotics 
Purified antibacterial enzymes have been described as enzybiotics i.e., as derived from 
‘antibiotic’. These can include extracellular polymeric substance (EPS) depolymerases (as 
above) but also, phage-encoded lytic enzymes, i.e., lysins. Though some lysins are virion-
particle associated, as are many EPS depolymerases the majority are endolysins, meaning 
“from-within cell-wall degrading enzymes. Enzybiotics upon purification, however, are 
applied from without. 
The peptidoglycan of Gram-positive bacteria is not protected by an outer membrane so is 
directly susceptible to phage lysins 
 
9) Clinical phage therapy 
Clinical phage therapy is the treatment or prevention of infections in honeybees and the 
use of phages in microbiome modification. Also is the related use of phages to treat or 
prevent infections in animals 
 
10) Biological control of bacteria using phages  
Phage biocontrol of bacterial crop and animal diseases is compared to chemical control 
measures. Phages they suggest are more environmentally friendly, can be tailored against 
specific disease-causing bacteria, and can be easily reformulated if resistance develops. 
 




Formation of biofilms during bacterial infection is one of the major problems in infection 
control. Bacteria in biofilms are extremely resistant to antimicrobials, well protected from 
host defenses, and tend to develop chronic infections. Some bacteriophages penetrate 





I the face of the alarming antibiotic crisis, phage therapy deserves serious consideration. 
Hopefully phages can prove as revolucionary in the veterinarian field as they have in the 
scientific.  
